糖尿病进展及其对肾癌风险的影响:来自韩国纵向队列研究的见解
该研究利用韩国国家健康信息数据库,分析2015至2016年接受健康检查的2 365 294例2型糖尿病患者,随访至2022年。糖尿病进展评分(0-6分)越高,肾癌风险越高,评分4分及以上者调整HR为1.73(95%CI 1.49-2.01)。
要点
- 糖尿病病程长、合并慢性肾脏病或糖尿病视网膜病变与肾癌风险升高相关。
- 糖尿病进展评分0-6分,评分越高肾癌风险越高,4分及以上调整HR为1.73(95%CI 1.49-2.01)。
- 作者认为应针对晚期糖尿病患者开展肾癌靶向筛查和意识提升项目。
核心结论
- 糖尿病进展与肾癌风险升高强烈相关。
- 作者认为这些发现强调了针对晚期糖尿病患者开展肾癌靶向筛查和意识提升项目的重要性。
研究设计与样本
- 使用韩国国家健康信息数据库的纵向队列研究,纳入2015年和2016年接受健康检查的2 365 294例2型糖尿病患者,排除已有癌症或一年内死亡者,随访至2022年。
- 糖尿病进展采用评分系统(范围0-6分)评估,基于口服降糖药数量、糖尿病病程、胰岛素使用以及慢性肾脏病、糖尿病视网膜病变或心血管疾病的存在。
- 肾癌发生定义为ICD-10编码C64。
主要发现
- 在糖尿病进展指标中,糖尿病病程延长以及慢性肾脏病或糖尿病视网膜病变的存在与肾癌风险比升高相关。
- 与评分0分者相比,肾癌调整HR为:评分1分1.21(95%CI 1.13-1.30),评分2分1.28(95%CI 1.18-1.38),评分3分1.37(95%CI 1.23-1.51),评分4分及以上1.73(95%CI 1.49-2.01)。
关键数值与推荐
- 糖尿病进展评分0-6分,评分越高肾癌风险越高。
- 与评分0分相比,评分4分及以上者肾癌调整HR为1.73(95%CI 1.49-2.01)。
临床怎么用
- 作者认为应针对晚期糖尿病患者开展肾癌靶向筛查和意识提升项目。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The incidence of kidney cancer is rising in Korea, with lifestyle and metabolic factors such as smoking, obesity, and hypertension contributing to this trend. OBJECTIVE: This study assessed the relationship between diabetes progression and kidney cancer risk. METHODS: Using data from the National Health Information Database in South Korea, analyzing 2 365 294 patients with type 2 diabetes mellitus who underwent health examinations in 2015 and 2016, excluding those with pre-existing cancer or who died within a year. Patients were monitored until 2022 to determine the incidence of kidney cancer, defined by ICD-10 code C64. Diabetes progression was assessed using a scoring system (range 0-6) based on the number of oral glucose-lowering drugs (GLDs), diabetes duration, insulin use, and the presence of chronic kidney disease (CKD), diabetic retinopathy (DR), or cardiovascular disease. RESULTS: Among the indicators of diabetes progression, prolonged diabetes duration and the presence of CKD or DR were linked to higher hazard ratios (HRs) for kidney cancer. The risk of kidney cancer increased progressively with higher diabetes progression scores. Compared to participants with a score of 0, the adjusted HRs for kidney cancer were 1.21 (95% CI 1.13-1.30) for a score of 1, 1.28 (1.18-1.38) for a score of 2, 1.37 (1.23-1.51) for a score of 3, and 1.73 (1.49-2.01) for scores of 4 or higher. CONCLUSION: Diabetes progression is strongly associated with an increased risk of kidney cancer. These findings underscore the importance of targeted screening and awareness programs for kidney cancer in individuals with advanced diabetes.
引用
- Yu J, Kim B, Han K, et al. Diabetes Progression and Its Impact on Kidney Cancer Risk: Insights From a Longitudinal Korean Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 40459059. doi:10.1210/clinem/dgaf249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。